45.65 USD
↘ 2.24 (4.68%)AT CLOSE (03:59 PM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
45.71
↗ 0.06 (0.13%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
45.71
↗ 0.06 (0.13%)
Market: CLOSED
AnaptysBio, Inc. Common Stock (ANAB) trades at $45.68 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 7, 2026.
Open?$47.00
High?$47.39
Low?$45.62
Prev. Close?$47.89
Volume?766.5K
Avg. Volume?549.1K
VWAP?$46.19
Rel. Volume?1.40x
Bid / Ask
Bid?$27.91 × 100
Ask?$54.15 × 100
Spread?$26.24
Midpoint?$41.03
Valuation & Ratios
Market Cap?1.4B
Shares Out?29.9M
Float?17.5M
Float %?59.0%
P/E Ratio?N/A
P/B Ratio?112.32
EPS?-$0.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?16
Momentum?50
Short Sent.?30
Piotroski F-Score?1/9Weak
Altman Z-Score?1.32Distress
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?31.14%Squeeze Risk
Short Interest?5.4M
Days to Cover?10.3
Free Float17.5M
Avg Daily Volume530.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score47/100
P/E?N/A▾
P/B?112.32HIGH▾
Peers100
S&P3
P/S?6.16FAIR▾
Peers100
S&P21
P/FCF?324.7PRICEY▾
Peers100
S&P3
EV/EBITDA?28.6HIGH▾
Peers100
S&P11
EV/Sales?5.09FAIR▾
Peers100
S&P35
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.2B
Fundamentals ratios updated end of day